Belén Garijo was appointed CEO of Sanofi, replacing Paul Hudson after his six-year tenure ended on February 17, 2026
John Tsai joined Daiichi Sankyo as global head of R&D from Novartis, where he oversaw development of 160 new projects and 500 clinical trials
Mark Dawson was named head of pharma research and early development at Roche, joining from Peter MacCallum Cancer Centre where he led development of first-in-class epigenetic therapies
Dr. Geoff McDonough became CEO of NodThera, a Boston-based biotech focused on chronic inflammatory diseases
Dr. Adam Rogers was confirmed as president and CEO of NervGen Pharma, a clinical-stage company developing neuroreparative therapeutics for spinal cord injury
Hans Schambe joined BOOST Pharma as CEO, bringing experience from Galecto Inc. where he raised over $500 million
Michael Cola became CEO of Helus Pharma with over 30 years of experience in neuroscience and rare disease
Multiple appointments were made to chief medical officer and chief scientific officer roles across biotech companies including Alterome Therapeutics, Oryzon, and Nucleome Therapeutics